J 2013

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

MOHELNIKOVA-DUCHONOVA, Beatrice, Veronika BRYNYCHOVA, Viktor HLAVAC, Matej KOCIK, Martin OLIVERIUS et. al.

Basic information

Original name

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

Authors

MOHELNIKOVA-DUCHONOVA, Beatrice (203 Czech Republic), Veronika BRYNYCHOVA (203 Czech Republic), Viktor HLAVAC (203 Czech Republic), Matej KOCIK (203 Czech Republic), Martin OLIVERIUS (203 Czech Republic), Jan HLAVSA (203 Czech Republic, guarantor, belonging to the institution), Eva HONSOVA (203 Czech Republic), Jan MAZANEC (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic) and Pavel SOUCEK (203 Czech Republic)

Edition

CANCER CHEMOTHERAPY AND PHARMACOLOGY, NEW YORK, SPRINGER, 2013, 0344-5704

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.571

RIV identification code

RIV/00216224:14110/13:00071472

Organization unit

Faculty of Medicine

DOI

UT WoS

000323653600019

Keywords in English

Pancreatic cancer; SLC transporters; Gene expression; Survival; KRAS

Tags

International impact, Reviewed
Změněno: 3/2/2014 13:32, Soňa Böhmová

Abstract

V originále

The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis. The study found that a high expression of SLC28A1 was significantly associated with poor overall survival in unselected patients. In contrast, a high expression of SLC22A3 or SLC29A3 was significantly associated with longer overall survival in patients treated with nucleoside analogs. Protein expression of SLC22A1, SLC22A3 and SLC29A3 in tumor tissues of patients with pancreatic carcinoma was observed by immunoblotting for the first time. Finally, SLC levels were not found to be associated with KRAS mutation status in exon 2. This study identified a number of associations of transcript levels of SLCs with prognosis of pancreatic cancer patients.